Slingshot members are tracking this event:

Regeneron (REGN) and Sanofi (SNY) announce Dupixent (dupilumab) pivotal trial primary and secondary endpoints data for moderate-to-severe atopic dermatitis in children as young as 6 months

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Clinical Data 28% achieved clear or almost-clear skin compared to 4% with placebo (p<0.0001), the primary endpoint.

53% achieved 75% or greater overall disease improvement from baseline compared to 11% with placebo (p<0.0001), the co-primary endpoint outside of the U.S.

70% average improvement from baseline in overall disease severity (EASI) compared to 20% improvement with placebo (p<0.0001).

49% average improvement from baseline in itch compared to 2% improvement with placebo (p<0.0001).

Significantly improved measures of observed patient outcomes (including sleep, skin pain and health-related quality of life), as well as caregiver-reported health-related quality of life.

The trial demonstrated similar safety results to the known safety profile of Dupixent in atopic dermatitis. For the 16-week treatment period, overall rates of adverse events (AEs) were 64% for Dupixent and 74% for placebo. Most common AEs and AEs of special interest included nasopharyngitis (8% Dupixent, 9% placebo), upper respiratory tract infection (6% Dupixent, 8% placebo), conjunctivitis (5% Dupixent, 0% placebo), herpes viral infections (6% Dupixent, 5% placebo) and injection site reactions (2% Dupixent, 3% placebo).
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 30, 2021
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Dupixent, Dupilumab